Condition: Percutaneous Coronary Intervention · Platelet Aggregation Inhibitors · Coronary Artery Disease · Sponsor: Insel Gruppe AG, University Hospital Bern
The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation. The TAILOR-DAPT trial aims to investigate the benefits of a score-based decision-making algorithm to guide DAPT duration compared to a standard-of-care DAPT duration without the use of risk scores in patients undergoing PCI.
This description comes directly from the study's public registry record.
Lorenz Räber, MD, PhD · +41 31 632 09 29 · Lorenz.raeber@insel.ch
Miklos Rohla, MD, PhD · +41 31 632 21 11 · miklos.rohla@insel.ch
Always discuss trial participation with your own doctor first.
| University Clinical Center of the Republic of Srpska | Banja Luka, Bosnia and Herzegovina | Recruiting |
| UOC Cardiologia San Giovanni Addolorata Hospital | Roma, Italy | Recruiting |
| Department of Cardiology, Bern University Hospital | Bern, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05732701